
Livsayis won approval for adults with anti-AChR-positive generalized myasthenia gravis, based on Phase 3 results reported by Regeneron.
Regeneron said the FDA approved Livsayis for adults with anti-AChR-positive generalized myasthenia gravis. The company says it is the first approved siRNA therapy for the condition and the only FDA-approved gMG treatment given by under-the-skin injection four times a year.
The decision was based on the Phase 3 NIMBLE trial. At 24 weeks, the drug improved patients’ MG-ADL scores by 4.5 points on average, compared with 2.2 points for placebo, according to Regeneron.
The drug’s prescribing information carries a boxed warning about serious meningococcal infections. Livsayis is available through a restricted safety program, the company said.
A regulatory submission for the treatment is under review in the European Union, with a decision anticipated in the second half of 2027.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.